Last 12 months
Inside the activity.
5 purchase rows · 8 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 5 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2025 Filed Mar 6, 2025 22:40 UTC |
Lampropoulos Fred P.Director · President and CEO
|
SaleCommon Stock, No Par Value | 2,590.001 | $103.75 | $268,712.60 |
DisclosureSEC source: 0001415889-25-007272 · form4-03062025_100305.xml · nonDerivative · entry 6 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 7,734.258 F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:40 UTC |
Lampropoulos Fred P.Director · President and CEO
|
SaleCommon Stock, No Par Value | 409.741 | $103.75 | $42,510.63 |
DisclosureSEC source: 0001415889-25-007272 · form4-03062025_100305.xml · nonDerivative · entry 5 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 10,324.259 F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:40 UTC |
Lampropoulos Fred P.Director · President and CEO
|
SaleCommon Stock, No Par Value | 20,000 | $103.75 | $2,075,000.00 |
DisclosureSEC source: 0001415889-25-007272 · form4-03062025_100305.xml · nonDerivative · entry 4 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,086,028 F4 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.75 to $103.765, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:40 UTC |
Lampropoulos Fred P.Director · President and CEO
|
SaleCommon Stock, No Par Value | 11,320 | $104.05 | $1,177,846.00 |
DisclosureSEC source: 0001415889-25-007272 · form4-03062025_100305.xml · nonDerivative · entry 3 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,106,028 F3 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.00 to $104.22, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:38 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 30,000 | $0.00 Strike: $55.73 | $0.00 |
DisclosureSEC source: 0001415889-25-007268 · form4-03062025_100333.xml · derivative · entry 4 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Become exercisable in equal annual installments of 20% commencing on 03/01/2020. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:38 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
SaleCommon Stock, No Par Value | 30,000 | $102.90 | $3,087,000.00 |
DisclosureSEC source: 0001415889-25-007268 · form4-03062025_100333.xml · nonDerivative · entry 3 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,945 F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.92 to $103.36, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:38 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
Exercise / conversionCommon Stock, No Par Value | 30,000 | $55.73 | $1,671,900.00 |
DisclosureSEC source: 0001415889-25-007268 · form4-03062025_100333.xml · nonDerivative · entry 2 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:41 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
GiftCommon Stock, No Par Value | 620 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007275 · form4-03062025_100307.xml · nonDerivative · entry 2 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,779 Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:38 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
GiftCommon Stock, No Par Value | 48 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007268 · form4-03062025_100333.xml · nonDerivative · entry 1 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,945 Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 02:07 UTC |
Peterson Neil W.CHIEF OPERATING OFFICER
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 5,000 | $0.00 Strike: $54.40 | $0.00 |
DisclosureSEC source: 0001415889-25-006831 · form4-03052025_020313.xml · derivative · entry 3 Peterson Neil · CIK 0001926221 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 15,000 shares Expires 2026-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2024. F2 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 04/25/2020. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 02:07 UTC |
Peterson Neil W.CHIEF OPERATING OFFICER
|
SaleCommon Stock, No Par Value | 5,000 | $105.00 | $525,000.00 |
DisclosureSEC source: 0001415889-25-006831 · form4-03052025_020313.xml · nonDerivative · entry 2 Peterson Neil · CIK 0001926221 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,369 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 02:07 UTC |
Peterson Neil W.CHIEF OPERATING OFFICER
|
Exercise / conversionCommon Stock, No Par Value | 5,000 | $54.40 | $272,000.00 |
DisclosureSEC source: 0001415889-25-006831 · form4-03052025_020313.xml · nonDerivative · entry 1 Peterson Neil · CIK 0001926221 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 02:06 UTC |
Evans Stephen C.Director
|
SaleCommon Stock, No Par Value | 5,000 | $105.31 | $526,550.00 |
DisclosureSEC source: 0001415889-25-006829 · form4-03052025_020318.xml · nonDerivative · entry 1 Evans Stephen C. · CIK 0001844301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,657 F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.07 to $105.71, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:26 UTC |
Peterson Neil W.CHIEF OPERATING OFFICER
|
GrantCommon Stock, No Par Value | 6,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006313 · form4-03042025_010318.xml · nonDerivative · entry 3 Peterson Neil · CIK 0001926221 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,369 F3 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of Common Stock upon vesting. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:24 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 25,000 | $0.00 Strike: $44.80 | $0.00 |
DisclosureSEC source: 0001415889-25-006311 · form4-03042025_010352.xml · derivative · entry 6 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Become exercisable in equal annual installments of 20% commencing on 03/02/2019. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:24 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
SaleCommon Stock, No Par Value | 25,000 | $99.50 | $2,487,500.00 |
DisclosureSEC source: 0001415889-25-006311 · form4-03042025_010352.xml · nonDerivative · entry 5 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,993 F4 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.56 to $100.0525, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:24 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
Exercise / conversionCommon Stock, No Par Value | 25,000 | $44.80 | $1,120,000.00 |
DisclosureSEC source: 0001415889-25-006311 · form4-03042025_010352.xml · nonDerivative · entry 4 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:24 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
GrantCommon Stock, No Par Value | 7,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006311 · form4-03042025_010352.xml · nonDerivative · entry 3 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,993 F3 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of Common Stock upon vesting. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 2,500 | $0.00 Strike: $70.58 | $0.00 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · derivative · entry 11 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,076 Underlying: Common Stock · 13,576 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Become exercisable in equal annual installments of 25% commencing on 02/28/2024. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 4,048 | $0.00 Strike: $65.03 | $0.00 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · derivative · entry 10 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,046 Underlying: Common Stock · 8,094 shares Expires 2029-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Becomes exercisable in equal annual installments of 25% commencing 02/28/2023. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 7,261 | $0.00 Strike: $56.25 | $0.00 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · derivative · entry 9 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,420 Underlying: Common Stock · 9,681 shares Expires 2028-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Become exercisable in equal annual installments of 25% commencing on 03/19/2022. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
SaleCommon Stock, No Par Value | 13,809 | $99.68 | $1,376,481.12 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · nonDerivative · entry 8 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,399 F5 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.425 to $100.485, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
Exercise / conversionCommon Stock, No Par Value | 2,500 | $70.58 | $176,450.00 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · nonDerivative · entry 7 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
Exercise / conversionCommon Stock, No Par Value | 4,048 | $65.03 | $263,241.44 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · nonDerivative · entry 6 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
Exercise / conversionCommon Stock, No Par Value | 7,261 | $56.25 | $408,431.25 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · nonDerivative · entry 5 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
GrantCommon Stock, No Par Value | 5,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · nonDerivative · entry 4 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,399 F4 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of Common Stock upon vesting. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:23 UTC |
Lampropoulos Fred P.Director · President and CEO
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 4,000 | $0.00 Strike: $44.80 | $0.00 |
DisclosureSEC source: 0001415889-25-006309 · form4-03042025_010339.xml · derivative · entry 11 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2025-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/2/2019. Options not vested as of 6/22/2020 have been forfeited. F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:23 UTC |
Lampropoulos Fred P.Director · President and CEO
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 38,002 | $0.00 Strike: $44.80 | $0.00 |
DisclosureSEC source: 0001415889-25-006309 · form4-03042025_010339.xml · derivative · entry 10 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,002 shares Expires 2025-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 3/2/2019. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:23 UTC |
Lampropoulos Fred P.Director · President and CEO
|
Tax withholdingCommon Stock, No Par Value | 2,494 | $102.04 | $254,487.76 |
DisclosureSEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 9 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 10,734 F7 · shares: The Reporting Person's spouse surrendered 2,494 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market. F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:23 UTC |
Lampropoulos Fred P.Director · President and CEO
|
Exercise / conversionCommon Stock, No Par Value | 4,000 | $44.80 | $179,200.00 |
DisclosureSEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 8 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 13,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:23 UTC |
Lampropoulos Fred P.Director · President and CEO
|
Tax withholdingCommon Stock, No Par Value | 26,043 | $102.04 | $2,657,427.72 |
DisclosureSEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 7 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,117,348 F6 · shares: The Reporting Person surrendered 26,043 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:23 UTC |
Lampropoulos Fred P.Director · President and CEO
|
Exercise / conversionCommon Stock, No Par Value | 38,002 | $44.80 | $1,702,489.60 |
DisclosureSEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 6 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,143,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:23 UTC |
Lampropoulos Fred P.Director · President and CEO
|
GrantCommon Stock, No Par Value | 20,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 5 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,105,389 F5 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of Common Stock upon vesting. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:20 UTC |
Parra Raul Jr.CFO AND TREASURER
|
SaleCommon Stock, No Par Value | 12,451 | $98.81 | $1,230,283.31 |
DisclosureSEC source: 0001415889-25-006304 · form4-03042025_010355.xml · nonDerivative · entry 5 Parra Raul Jr. · CIK 0001742555 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,201 F5 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.09 to $99.345, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:20 UTC |
Parra Raul Jr.CFO AND TREASURER
|
GrantCommon Stock, No Par Value | 7,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006304 · form4-03042025_010355.xml · nonDerivative · entry 4 Parra Raul Jr. · CIK 0001742555 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,652 F4 · shares: Represents a grant of restricted stock units ("RSUs"). The RSUs vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of Common Stock upon vesting. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:19 UTC |
Gunderson Thomas J.Director
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 25,000 | $0.00 Strike: $50.50 | $0.00 |
DisclosureSEC source: 0001415889-25-006302 · form4-03042025_010348.xml · derivative · entry 3 Gunderson Thomas James · CIK 0001708144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 06/07/2019. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:19 UTC |
Gunderson Thomas J.Director
|
Tax withholdingCommon Stock, No Par Value | 12,806 | $99.95 | $1,279,959.70 |
DisclosureSEC source: 0001415889-25-006302 · form4-03042025_010348.xml · nonDerivative · entry 2 Gunderson Thomas James · CIK 0001708144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,882 F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.60 to $100.515, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 01:19 UTC |
Gunderson Thomas J.Director
|
Exercise / conversionCommon Stock, No Par Value | 25,000 | $50.50 | $1,262,500.00 |
DisclosureSEC source: 0001415889-25-006302 · form4-03042025_010348.xml · nonDerivative · entry 1 Gunderson Thomas James · CIK 0001708144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:26 UTC |
Peterson Neil W.CHIEF OPERATING OFFICER
|
Tax withholdingCommon Stock, No Par Value | 4,255 | $98.50 | $419,117.50 |
DisclosureSEC source: 0001415889-25-006313 · form4-03042025_010318.xml · nonDerivative · entry 2 Peterson Neil · CIK 0001926221 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,097 F2 · shares: The Reporting Person surrendered 4,255 shares of common stock to the Issuer for payroll taxes. No shares were sold in the open market. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:26 UTC |
Peterson Neil W.CHIEF OPERATING OFFICER
|
GrantCommon Stock, No Par Value | 11,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006313 · form4-03042025_010318.xml · nonDerivative · entry 1 Peterson Neil · CIK 0001926221 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,352 F1 · shares: These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02.28.2022. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:24 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
Tax withholdingCommon Stock, No Par Value | 4,198 | $98.50 | $413,503.00 |
DisclosureSEC source: 0001415889-25-006311 · form4-03042025_010352.xml · nonDerivative · entry 2 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,937 F2 · shares: The Reporting Person surrendered 4,198 shares of common stock to the Issuer for payroll taxes. No shares were sold in the open market. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:24 UTC |
Lloyd Brian G.CHIEF LEGAL OFFICER, SECRETARY
|
GrantCommon Stock, No Par Value | 11,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006311 · form4-03042025_010352.xml · nonDerivative · entry 1 Lloyd Brian G. · CIK 0001671772 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,135 F1 · shares: These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02.28.2022. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
Tax withholdingCommon Stock, No Par Value | 4,530 | $98.50 | $446,205.00 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · nonDerivative · entry 3 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,911 F3 · shares: The Reporting Person surrendered 4,530 shares of common stock to the Issuer for payroll taxes. No shares were sold in the open market. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:22 UTC |
Voigt Michel J.CHIEF HUMAN RESOURCES OFFICER
|
GrantCommon Stock, No Par Value | 11,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006307 · form4-03042025_010329.xml · nonDerivative · entry 2 Voigt Michel James · CIK 0001836958 · CHIEF HUMAN RESOURCES OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,441 F2 · shares: These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02.28.2022. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:23 UTC |
Lampropoulos Fred P.Director · President and CEO
|
Tax withholdingCommon Stock, No Par Value | 13,501 | $98.50 | $1,329,848.50 |
DisclosureSEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 4 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,085,005 F4 · shares: The Reporting Person surrendered 13,051 shares of common stock to the Issuer for payroll taxes. No shares were sold in the open market. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:23 UTC |
Lampropoulos Fred P.Director · President and CEO
|
GrantCommon Stock, No Par Value | 30,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006309 · form4-03042025_010339.xml · nonDerivative · entry 3 LAMPROPOULOS FRED P · CIK 0000901534 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,098,506 F3 · shares: These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02/28/2022. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:20 UTC |
Parra Raul Jr.CFO AND TREASURER
|
Tax withholdingCommon Stock, No Par Value | 8,309 | $98.50 | $818,436.50 |
DisclosureSEC source: 0001415889-25-006304 · form4-03042025_010355.xml · nonDerivative · entry 3 Parra Raul Jr. · CIK 0001742555 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,812 F3 · shares: The Reporting Person surrendered 8,309 shares of common stock to the Issuer for payroll taxes. No shares were sold in the open market. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:20 UTC |
Parra Raul Jr.CFO AND TREASURER
|
GrantCommon Stock, No Par Value | 20,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006304 · form4-03042025_010355.xml · nonDerivative · entry 2 Parra Raul Jr. · CIK 0001742555 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,121 F2 · shares: These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02.28.2022. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 20:59 UTC |
Millner F. Ann Ed.D.Director
|
Exercise / conversionNon-qualified stock options (right to buy) · Derivative | 12,500 | $0.00 Strike: $50.50 | $0.00 |
DisclosureSEC source: 0001415889-24-027066 · form4-11182024_081155.xml · derivative · entry 3 Millner F. Ann · CIK 0001649014 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2025-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2023. F3 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 06/07/2019. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 20:59 UTC |
Millner F. Ann Ed.D.Director
|
SaleCommon Stock, No Par Value | 12,500 | $101.55 | $1,269,375.00 |
DisclosureSEC source: 0001415889-24-027066 · form4-11182024_081155.xml · nonDerivative · entry 2 Millner F. Ann · CIK 0001649014 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,391 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2023. F2 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.78 to $101.97, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.